

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-118. (canceled)

119. (currently amended): A method for administration of a substance to the intradermal space of a mammal, the method comprising injecting the substance into the intradermal space of the mammal through at least one hollow needle comprising a ~~an~~ needle outlet at a depth of about 0.3 mm to about 2.5 mm, wherein the outlet has an exposed height from 0 mm to about 1 mm, and wherein improved systemic absorption is obtained ~~produced~~ relative to absorption ~~produced~~ upon injecting the substance subcutaneously, and wherein the substance is a growth hormone, low molecular weight heparin, or a dopamine receptor agonist.

120. (previously presented): The method of claim 119, wherein the substance is administered as a bolus.

121. (previously presented): The method of claim 119, wherein the substance is administered by infusion.

Claims 122-126 (canceled)

127. (previously presented): The method of claim 119, wherein the substance is in the form of nanoparticles.

128. (previously presented): The method of claim 119, wherein the at least one hollow needle comprises an array of microneedles.

129. (previously presented): The method of claim 119, wherein the exposed height of the needle outlet is 0 mm.

130. (previously presented): The method of claim 119, wherein the needle outlet is formed by a bevel.

131. (previously presented): The method of claim 119, wherein the needle outlet is formed by an opening in the side of the needle.

132. (currently amended): A method for administration of a substance ~~drug~~ to a human subject, comprising delivering the substance ~~drug~~ through the lumen of a hollow needle into an intradermal compartment of the human subject's skin, which method comprises

(a) inserting the needle into the subject's skin so that the needle penetrates the intradermal compartment, and the needle's outlet depth and exposed height of the outlet are located within the intradermal compartment, wherein the outlet has an exposed height of about 0 to 1 mm; and

(b) delivering the substance ~~drug~~ through the lumen of the needle with the application of pressure in an amount effective to control the rate of delivery of the substance ~~drug~~,

so that the substance ~~drug~~ is delivered through the lumen of the needle into the intradermal compartment and distributed systemically exhibiting a higher maximum plasma concentration and a higher bioavailability as compared to subcutaneous delivery of the substance ~~drug~~, and wherein the substance is a growth hormone, low molecular weight heparin, or a dopamine receptor agonist.

133. (currently amended): The method of claim 132, wherein the needle is selected from the group consisting of a microneedle ~~microneedles~~, a catheter ~~needle~~ ~~needles~~, and an injection ~~needle~~ ~~needles~~.

134. (previously presented): The method of claim 132, wherein a single needle is inserted.

135. (previously presented): The method of claim 132, wherein multiple needles are inserted.

136. (previously presented): The method of claim 132, wherein the substance is a liquid delivered by pressure directly on the liquid.

137. (canceled)

138. (canceled)

139. (previously presented): The method of claim 132, wherein the needle has a length from about 0.5 to about 1.7 mm.

140. (previously presented): The method of claim 132, wherein the needle's outlet depth is between about 0.3 mm to 2 mm when the needle is inserted.

141. (previously presented): The method of claim 132, wherein the outlet has an exposed height of 0 mm.

142. (previously presented): The method of claim 132, wherein the delivery rate or volume is controlled by spacing of multiple needles.